“If all you have is a hammer, everything looks like a nail”

It was called “instrument bias” by Abraham Maslow and Abraham Kaplan, but for present purposes, we’ll call it “specialty bias” — over-reliance on the tool one is most familiar with. … READ MORE …

Suggestions of bias in decisions about who got biopsies in the SELECT trial

A re-analysis of data from men participating in the placebo arms of the Prostate Cancer Prevention Trial (PCPT) and the Selenium and Vitamin E Cancer Prevention Trial (SELECT) has suggested a problem with bias in decisions about who gets biopsies during certain types of clinical trial. … READ MORE …

Physicians’ attitudes and the management of low-risk prostate cancer in older American men

According to newly published data in JAMA Internal Medicine and discussed on the Reuters web site today, “physician characteristics may play a larger role than disease characteristics when it comes to how patients with low-risk prostate cancer are initially treated.” This won’t come as a big surprise to most experienced prostate cancer advocates. … READ MORE …

Did unequal use of ADT in treatment affect mortality rates in the ERSPC and Göteborg trials?

A new article by Australian researchers in the Journal of the National Cancer Institute has suggested that the more widespread use of androgen deprivation therapy (ADT) among unscreened patients (controls) in the ERSPC and the Göteborg studies may have substantially affected patient mortality data in these trials. … READ MORE …

Shopping for care in the prostate cancer “treatment bazaar”

A recent article (and an associated editorial) in the Archives of Internal Medicine evaluated how visits to specialists and primary care physicians (PCPs) by men with localized prostate cancer are related to treatment choice. … READ MORE …

Prostate cancer news reports: Tuesday, May 19, 2009

Today’s reports address:

  • How German prostate cancer specialists would treat themselves
  • Identification of patients appropriate for focal therapy
  • Italian management of men with an elevated PSA level
  • Triple therapy for men with T3a,b disease … READ MORE …